Loading
Protara Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 16 May 2025.
Protara Therapeutics, Inc.: what insiders have been doing
Protara Therapeutics, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). Between 18 October 2025 and 18 October 2026, 7 insiders published 18 filings.
There is no open-market purchase to report; the filings show 2 sales worth €108k by 1 insider. Biggest ticket of the year: €103k, sold by Zummo Jacqueline and made public on 2 April 2026.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 18 filings, this issuer sits below that mark. The full history, which starts in 2016, counts 15 purchases against 16 sales.
Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
100
Thresholds
n/a
Buy Volume
€527,567
15 ops. · all time
Sell Volume
€810,287
16 ops. · all time
Who traded when
BuySaleJacqueline Zummo3 sales
Richard S. Levy1 buy
Since the insiders bought
- +34.5%Entry US$3.42 · Close at T+365 US$4.60
- -28.9%Entry US$3.25 · Close at T+365 US$2.31
- -37.6%Entry US$4.87 · Close at T+365 US$3.04
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Protara Therapeutics, Inc. Strong Buy (bullish), based on 7 analysts. Average price target: US$25.71.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.40
Analyst consensus
7 analystsStrong buy
US$20.00Target US$25.71(+971%)US$30.00
Income statement
EBITDA-US$64.2M
Net income-US$57.4M0.0% margin
Valuation
PER (forward)-1.4x
P/Book0.9x
Beta1.47
Balance sheet & cash
Market capUS$141.8M
Total debtUS$3.4M
Free Cash Flow-US$56.5M
Debt / Equity2%
Profitability & ownership
ROE-45.8%
ROA-28.8%
% insiders2.3%
% institutions78.4%
Last declaration on 29 June 2026
Declarations100 total
215,687 shares@ US$4.08930.45% mcap100.0% of flowCommonSEC144:0001950047-26-006626
6,008 shares@ US$4.340.011% mcap100.0% of flowCommon StockSEC:0001213900-26-064792:0
1,134 shares@ US$5.401.5% of flowCommon StockSEC:0001213900-26-042079:0
22,598 shares@ US$5.2629.0% of flowCommon StockSEC:0001213900-26-039328:0
8,732 shares@ US$6.6713.8% of flowCommon StockSEC:0001213900-26-008224:0
3,724 shares@ US$6.675.9% of flowCommon StockSEC:0001213900-26-008223:0
1,457 shares@ US$6.6714.9% of flowCommon StockSEC:0001213900-26-008222:0
3,261 shares@ US$6.6739.0% of flowCommon StockSEC:0001213900-26-008221:0
16,322 shares@ US$5.6022.0% of flowCommon StockSEC:0001213900-26-006711:0
3,063 shares@ US$5.6031.3% of flowCommon StockSEC:0001213900-26-006709:0
6,578 shares@ US$5.609.0% of flowCommon StockSEC:0001213900-26-006708:0
2,132 shares@ US$5.6018.6% of flowCommon StockSEC:0001213900-26-006707:0
26,000 shares0Common StockSEC:0001213900-26-006231:0
28,000 shares0Common StockSEC:0001213900-26-006230:0
9,500 shares0Common StockSEC:0001213900-26-006229:0
26,000 shares0Common StockSEC:0001213900-26-006228:0
87,000 shares0Common StockSEC:0001213900-26-006226:0
30,000 shares0Common StockSEC:0001213900-26-006225:0
300,000 shares0Common StockSEC:0001213900-25-061772:0
1,700 shares0Common StockSEC:0001213900-25-059655:0
50,000 shares0Common StockSEC:0001213900-25-051157:0
20,000 shares@ US$3.19100.0% of flowCommon StockSEC:0001213900-25-044871:0
Canonical exit: 12 Aug 2025 (T+90)
50,000 shares0Common StockSEC:0001213900-25-032965:0
21,224 shares@ US$4.5325.2% of flowCommon StockSEC:0001013762-25-004101:0
24,500 shares0Common StockSEC:0001213900-25-007532:0
25 of 100 declarations
About Protara Therapeutics, Inc.
Protara Therapeutics, Inc. is a U.S.-based clinical-stage biotechnology company listed on the Nasdaq market in the United States under ticker TARA. From an equity analyst’s perspective, Protara should be viewed as a development-stage specialty pharma/biotech name rather than a commercial company: its investment case is driven primarily by clinical readouts, regulatory progress, and financing capacity, not by recurring product revenue. The company’s profile is typical of Nasdaq-listed biotechs where valuation is highly sensitive to trial data and FDA interactions. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1359931/000121390026025432/ea028040401ex99-1.htm?utm_source=openai))
The company is headquartered in New York City, New York. Its strategy is centered on two lead programs. The first is TARA-002, an intravesical therapy being developed for non-muscle invasive bladder cancer (NMIBC), including both BCG-unresponsive and BCG-naïve settings. The second is intravenous choline chloride, being studied for patients dependent on parenteral support. This focused pipeline gives Protara a relatively concentrated but potentially value-creating clinical portfolio, with the company’s near- to mid-term narrative tied to advancing these programs through late-stage development and, ultimately, toward potential registration. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1359931/000121390026025432/ea028040401ex99-1.htm?utm_source=openai))
Read moreShow less
Historically, Protara has been built as a biotechnology platform focused on differentiated assets in high-need indications. Rather than competing on breadth, it competes on specificity: it targets disease areas where existing treatment options remain limited or suboptimal, and where a well-tolerated therapy could gain meaningful clinical adoption if efficacy is confirmed. In bladder cancer, the competitive environment is crowded and scientifically demanding, so differentiation will depend on efficacy, safety, and ease of administration. In rare diseases such as lymphatic malformations, the opportunity is attractive because unmet need is high, but commercial success will depend on the strength of clinical evidence and the ability to translate early promise into regulatory momentum. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1359931/000121390026025432/ea028040401ex99-1.htm?utm_source=openai))
Recent milestones have been an important part of the story. In 2025 and 2026, Protara reported ongoing clinical progress across its pipeline, including updates for TARA-002 in NMIBC and lymphatic malformations, along with FDA designations that support the program’s development path. The company also strengthened its balance sheet through an equity financing in late 2025, improving cash visibility and reducing near-term funding pressure. For investors, the name remains a classic clinical-stage Nasdaq biotechnology story in the United States: promising science, meaningful upside optionality, but also binary trial and regulatory risk. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1359931/000121390026025432/ea028040401ex99-1.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
